# Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.

> **NCT00835081** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cefadroxil 500 mg Capsules
- **DRUG:** DURICEF® capsules 500 mg

## Key facts

- **NCT ID:** NCT00835081
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00835081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00835081, "Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00835081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*